These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 10467963)

  • 1. Effects of a novel pyridylsulphonyl thiazole derivative, FR115092, on autoimmune and mitomycin C-induced thrombocytopenia in mice.
    Nishigaki F; Tsujimoto S; Inami M; Matsumoto S; Naoe Y; Kawamura I; Manda T; Shimomura K
    J Pharm Pharmacol; 1999 Jul; 51(7):857-65. PubMed ID: 10467963
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis and effects of novel thiazole derivatives against thrombocytopenia.
    Tsuji K; Ogino T; Seki N; Sawada M; Sudo Y; Nishigaki F; Manda T; Matsuo M
    Bioorg Med Chem Lett; 1998 Sep; 8(18):2473-8. PubMed ID: 9873564
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune thrombocytopenia: antiplatelet autoantibodies inhibit proplatelet formation by megakaryocytes and impair platelet production in vitro.
    Iraqi M; Perdomo J; Yan F; Choi PY; Chong BH
    Haematologica; 2015 May; 100(5):623-32. PubMed ID: 25682608
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thiazolidinediones increase the number of platelets in immune thrombocytopenic purpura mice via inhibition of phagocytic activity of the reticulo-endothelial system.
    Kasono K; Nishida J; Tamemoto H; Fudaka K; Namai K; Kajio H; Masatoshi K; Kanazawa Y; Kawakami M
    Life Sci; 2002 Sep; 71(17):2037-52. PubMed ID: 12175897
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A mild transient decrease of peripheral red blood cell counts induced by a suprapharmacological dose of pegylated human megakaryocyte growth and development factor in rats.
    Harada K; Ide Y; Tazunoki Y; Imai A; Yanagida M; Kikuchi Y; Imai A; Ishii H; Kawahara J; Izumi H; Kusaka M; Tokiwa T
    J Pharm Pharmacol; 1999 Jul; 51(7):841-6. PubMed ID: 10467960
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacological characterization of cepharanthin in chronic idiopathic thrombocytopenic purpura.
    Sato T; Morita I; Fujita H; Ono M; Kimishima A; Tomiyama J; Murota S
    Platelets; 2001 May; 12(3):156-62. PubMed ID: 11304417
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The pathophysiology of ITP revisited: ineffective thrombopoiesis and the emerging role of thrombopoietin receptor agonists in the management of chronic immune thrombocytopenic purpura.
    Gernsheimer TB
    Hematology Am Soc Hematol Educ Program; 2008; ():219-26. PubMed ID: 19074086
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acquired amegakaryocytic thrombocytopenia previously diagnosed as idiopathic thrombocytopenic purpura in a patient with hepatitis C virus infection.
    Ichimata S; Kobayashi M; Honda K; Shibata S; Matsumoto A; Kanno H
    World J Gastroenterol; 2017 Sep; 23(35):6540-6545. PubMed ID: 29085203
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New-generation drugs that stimulate platelet production in chronic immune thrombocytopenic purpura.
    Nurden AT; Viallard JF; Nurden P
    Lancet; 2009 May; 373(9674):1562-9. PubMed ID: 19324405
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Autoimmune heparin-induced thrombocytopenia.
    Greinacher A; Selleng K; Warkentin TE
    J Thromb Haemost; 2017 Nov; 15(11):2099-2114. PubMed ID: 28846826
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low-dose decitabine promotes megakaryocyte maturation and platelet production in healthy controls and immune thrombocytopenia.
    Zhou H; Hou Y; Liu X; Qiu J; Feng Q; Wang Y; Zhang X; Min Y; Shao L; Liu X; Li G; Li L; Yang L; Xu S; Ni H; Peng J; Hou M
    Thromb Haemost; 2015 May; 113(5):1021-34. PubMed ID: 25566808
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The potential role of thrombopoietin in idiopathic thrombocytopenic purpura.
    von dem Borne A; Folman C; van den Oudenrijn S; Linthorst G; de Jong S; de Haas M
    Blood Rev; 2002 Mar; 16(1):57-9. PubMed ID: 11913997
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Autoimmune-prone (NZW x BXSB)F1 (W/BF1) mice escape severe thrombocytopenia after treatment with deoxyspergualin, an immunosuppressant.
    Nemoto K; Mae T; Saiga K; Matsuura E; Koike T
    Br J Haematol; 1995 Nov; 91(3):691-6. PubMed ID: 8555077
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiplatelet antibody-induced thrombocytopenia does not correlate with megakaryocyte abnormalities in murine immune thrombocytopenia.
    Guo L; Kapur R; Aslam R; Hunt K; Hou Y; Zufferey A; Speck ER; Rondina MT; Lazarus AH; Ni H; Semple JW
    Scand J Immunol; 2018 Jul; 88(1):e12678. PubMed ID: 29855061
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regulation of serum thrombopoietin levels by platelets and megakaryocytes in patients with aplastic anaemia and idiopathic thrombocytopenic purpura.
    Ichikawa N; Ishida F; Shimodaira S; Tahara T; Kato T; Kitano K
    Thromb Haemost; 1996 Aug; 76(2):156-60. PubMed ID: 8865522
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of a novel, small non-peptidyl molecule butyzamide on human thrombopoietin receptor and megakaryopoiesis.
    Nogami W; Yoshida H; Koizumi K; Yamada H; Abe K; Arimura A; Yamane N; Takahashi K; Yamane A; Oda A; Tanaka Y; Takemoto H; Ohnishi Y; Ikeda Y; Miyakawa Y
    Haematologica; 2008 Oct; 93(10):1495-504. PubMed ID: 18728031
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dapsone for chronic autoimmune thrombocytopenic purpura: a report of 66 cases.
    Godeau B; Durand JM; Roudot-Thoraval F; Tennezé A; Oksenhendler E; Kaplanski G; Schaeffer A; Bierling P
    Br J Haematol; 1997 May; 97(2):336-9. PubMed ID: 9163598
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of FR115092: a novel antinephritic agent.
    Ogino T; Tsuji K; Tojo T; Igari N; Seki N; Sudo Y; Manda T; Nishigaki F; Matsuo M
    Bioorg Med Chem Lett; 1998 Jan; 8(1):75-80. PubMed ID: 9871632
    [TBL] [Abstract][Full Text] [Related]  

  • 19. (NZW x BXSB)F1 mouse. A new animal model of idiopathic thrombocytopenic purpura.
    Oyaizu N; Yasumizu R; Miyama-Inaba M; Nomura S; Yoshida H; Miyawaki S; Shibata Y; Mitsuoka S; Yasunaga K; Morii S
    J Exp Med; 1988 Jun; 167(6):2017-22. PubMed ID: 3290385
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Energy restriction prevents and reverses immune thrombocytopenic purpura (ITP) and increases life span of ITP-prone (NZW x BXSB) F1 mice.
    Mizutani H; Engelman RW; Kurata Y; Ikehara S; Good RA
    J Nutr; 1994 Oct; 124(10):2016-23. PubMed ID: 7931711
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.